OncoMatch/Clinical Trials/NCT06918834
Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients
Is NCT06918834 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for myelodysplastic syndromes.
This study aims to evaluate whether immediate allogeneic hematopoietic stem cell transplantation (HSCT) is non-inferior to HSCT following bridging therapy in patients with higher-risk myelodysplastic syndrome (HR-MDS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Prior therapy
Cannot have received: allogeneic hematopoietic stem cell transplantation
Lab requirements
Kidney function
Estimated glomerular filtration rate (eGFR) <50 mL/min [excluded]
Liver function
Serum bilirubin >1.5x upper limit of normal (unless due to Gilbert syndrome) or AST/ALT >5x upper limit of normal [excluded]
Cardiac function
Left ventricular ejection fraction <50% [excluded]
Severe organ dysfunction: Left ventricular ejection fraction <50%. Oxygen supplementation requirement. Serum bilirubin >1.5x upper limit of normal (unless due to Gilbert syndrome) or AST/ALT >5x upper limit of normal. Estimated glomerular filtration rate (eGFR) <50 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06918834 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages